BCC022: Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Research Grant
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Pennsylvania State University
Start Date
December 8, 2025
End Date
December 7, 2026
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Pennsylvania State University
Start Date
December 8, 2025
End Date
December 7, 2026